Contents: News Stories, 1995 Phase II SBIR Grant Awarded to Nanoprobes, Incorporated (October 17, 1995) Browse the company news archive...   12/21/07: 1-Hr His-Tag Detection on Westerns 8/21/07: Review Paper: Enzmet for In Situ Hybridization 4/17/07: Announcing AuroVist: Xray Contrast for MicroCT 1/10/07: Phase 2 SBIR Grant for MicroCT Imaging   11/10/06: Gold X-Ray Contrast Agents 7/20/06: First 3D Distribution of 45S rDNA 3/15/06: Major Expansion Completed   9/5/03: New Product: Ni-NTA-Nanogold® 3/25/03: New Product: Alexa FluoroNanogold   9/9/02: NIH SBIR: MRI Contrast Agents 9/4/02: NIH STTR: Her-2/neu Assay 7/8/02: NIH SBIR: Molecular Beacons II   10/9/01: NIH SBIR: Enzyme Metallography 10/9/01: Reagents from Molecular Probes   9/5/00: NIH SBIR: Molecular Beacons 6/16/00: NIH STTR: Her-2/neu Amplification 4/19/00: Phase II of "Fast-Track" NIH SBIR grant 3/9/00: Larger Nanoprobes Facility 3/9/00: New NIH NCI SBIR Grant   11/15/99: New NIH NIDDK SBIR Grant 9/23/99: New NIH "Fast-Track" SBIR Grant 9/15/99: Gold Enhancement 9/15/99: Cy3-FluoroNanogold 1/29/99: NSF SBIR: Interconnect Fabrication   9/11/98: Phase I SBIR Grant 4/3/98: Phase II of "Fast-Track" SBIR Grant   9/8/97: "Fast-Track" SBIR Grant 9/5/97: New FluoroNanogold Papers 4/27/97: SBIR - Membrane Protein Labels.   10/7/96: SBIR - Ni-NTA-Gold probes 10/3/96: NIH Phase II SBIR 8/20/96: Ultrasensitive In Situ Hybridization 8/20/96: Gold Lipids 5/25/96: Nanogold-Peptide Probes 2/22/96: NSF Phase I SBIR to Nanoprobes   10/17/95: Phase II SBIR to Nanoprobes   10/94: 3, 5, 10, 15 and 30nm Colloidal Gold 9/94: FluoroNanogold 6/92: Nanogold® Gold Labeling Reagents   News Index

Reported by "Genetic Engineering News" (November 1, 1995), "Long Island Business News" (November 6, 1995), "BioCentury (The Bernstein Report on BioBusiness" (October 23, 1995) and "Biotechnology NETWORK" (newsletter of the New York Biotechnology Association: Winter 1996).

Phase II SBIR grant awarded to Nanoprobes, Incorporated

Large (1.8 to 3.6 nm) platinum and palladium cluster labels will be covalently attached to antibodies, antibody fragments and other targeted biomolecules. These new probes will combine the high cell penetration, minimal non-specific binding and high resolution of covalently linked gold cluster immunoprobes (already observed with the company's range of Nanogold® products) with the improved ease of visualization of the larger clusters.

As a second research strategy, targeted biomolecules will also be labeled with arrays of multiple gold clusters carried by compact, spherical polymers, to give ultrasensitive detection reagents for immunoblots and immunoassay tests. Because the new labels will be covalently attached, not adsorbed, potentially they may be conjugated to a wide range of small molecular probes and immunoassay reagents such as synthetically engineered peptides, lipids and oligonucleotides. This would generate new applications in electron microscopy, and new protocols for ultrasensitive screening and dignostic tests. The research will be directed by Dr. Richard D. Powell and performed in collaboration with Dr. David L. Spector of Cold Spring Harbor Laboratory (Cold Spring Harbor, NY) and Dr. Stephen M. Kaminsky of United Biomedical, Incorporated (Hauppauge, NY), with a subcontract to the State University of New York at Stony Brook, NY. In addition to the $ 717,245 Phase II SBIR award, a leveraged funding advance of $ 10,000 has been made by the Center for Biotechnology (SUNY at Stony Brook, NY) to further the goals of this project.

This grant follows an earlier Phase II SBIR award from the National Institutes of Health to Nanoprobes, Incorporated for $ 499,784 in 1994 for the development of combined fluorescent and gold immunoprobes. This project, which is performed in collaboration with Cold Spring Harbor Laboratory (Cold Spring Harbor, NY), the University of Massachusetts Medical Center (Worcester, MA) and the University of Illinois at Urbana-Champaign (Urbana, IL) may yield novel types of molecular probe labels containing both a gold cluster and a fluorophore. These would allow researchers to generate two complementary sets of data-from fluorescence microscopy and electron microscopy-from a single immunostaining experiment.

Nanoprobes, Incorporated, founded in November 1990, is a leader in immunogold technology. Current products include the 1.4 nm Nanogold® and 0.8 nm undecagold cluster immunoprobes and labeling reagents, gold-lipids, a complete range of colloidal gold probes, and a line of silver enhancement and negative staining reagents. The Company is a tenant of the Long Island High Technology Incubator at Stony Brook, New York.

Contact:

Richard D. Powell, Research Director

Tel.: (516) 444-8815
Fax: (516) 444-8815
E-mail nano@nanoprobes.com.
WWW: www.nanoprobes.com

contents